Emerging cancer-targeted therapies (Q35064126)

6 August 2017

1 reference

title

Emerging cancer-targeted therapies (English)

1 reference

6 August 2017

2

Timothy P Cripe

1 reference

6 August 2017

Robert J Arceci

1

1 reference

6 August 2017

publication date

1 December 2002

1 reference

Pediatric Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

49

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

1339-68, vii-viii

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Transgenic mice as a source of fully human antibodies for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Antibody humanization using monovalent phage display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapeutic applications of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

From molecular changes to customised therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Vaccine therapies for non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Immunotherapy of Non-Hodgkin's lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Monoclonal antibody-based therapy for neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Advances in immunotherapy of hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Mylotarg: antibody-targeted chemotherapy comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Trastuzumab/chemotherapy combinations in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Platinum compounds in the treatment of advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Can multidrug resistance mechanisms be modified?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Multidrug resistance in haematological malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Biologic response modifiers in pediatric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapeutic options in the management of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Interleukin-2: clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Tumor antigens recognized by T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Inducing autoimmune disease to treat cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The potential for antitumor vaccination in acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Immunologic mechanisms of antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Advances in cancer vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

WT1 as a novel target antigen for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Treatment of Epstein-Barr virus-associated malignancies with specific T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Adoptive cellular immunotherapy for EBV lymphoproliferative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Cancer vaccines and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Design and selection of vaccine adjuvants: animal models and human trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Cancer vaccines: progress reveals new complexities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Use of major histocompatibility complex class I tetramers to monitor tumor-specific cytotoxic T lymphocyte response in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

T-cell-directed cancer vaccines: the melanoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Replication-selective microbiological agents: fighting cancer with targeted germ warfare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Viruses as oncolytic agents: a new age for "therapeutic" viruses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A novel tetracycline-inducible viral replication switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Conditionally replicating herpes vectors for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Serous cutaneous glands in Phyllomedusa hypochondrialis (Anura, Hylidae): secretory patterns during ontogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Gene therapy death prompts review of adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Reports of adenovector "death" are greatly exaggerated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Reovirus therapy of tumors with activated Ras pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Reovirus as an oncolytic agent against experimental human malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Intergeneric poliovirus recombinants for the treatment of malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Overexpression of the CD155 gene in human colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

New developments in the virus therapy of cancer: a historical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Newcastle disease virus (NDV): brief history of its oncolytic strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Systemic therapy of myeloma xenografts by an attenuated measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Combination bacteriolytic therapy for the treatment of experimental tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Proliferation, cell cycle and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Oncogenic kinase signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Perspectives on the development of a molecularly targeted agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The roles of FLT3 in hematopoiesis and leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

7 January 2021

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

STI571 (Gleevec) as a paradigm for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Roots of clinical resistance to STI-571 cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Farnesyl transferase inhibitors as anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Anti-angiogenesis: new concept for therapy of solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Angiogenesis and anti-angiogenesis in neuroblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

The proto-oncogene Bcl-2 and its role in regulating apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Antisense therapy in oncology: new hope for an old idea?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Achilles' heel of cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Pharmacological rescue of mutant p53 conformation and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Antisense anticancer oligonucleotide therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapeutic exploitation of the p53 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

DNA methylation, chromatin inheritance, and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Histone deacetylases as therapeutic targets in hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Biology and treatment of acute progranulocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Differentiation therapy in acute myelogenous leukemia (non-APL).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Histone deacetylase as a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

DNA methylation: past, present and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900096-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(02)00096-2

1 reference

6 August 2017

1 reference